Oscar Health, Inc. (NYSE:OSCR – Get Free Report) CAO Victoria Baltrus sold 958 shares of the stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $31.45, for a total transaction of $30,129.10. Following the completion of the sale, the chief accounting officer directly owned 213,631 shares of the company’s stock, valued at $6,718,694.95. This represents a 0.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Oscar Health Price Performance
NYSE:OSCR traded up $0.65 during trading hours on Tuesday, hitting $32.90. 4,754,860 shares of the stock traded hands, compared to its average volume of 7,062,275. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 0.21. Oscar Health, Inc. has a 1 year low of $10.69 and a 1 year high of $33.55. The company has a market cap of $10.15 billion, a price-to-earnings ratio of 23.50, a price-to-earnings-growth ratio of 0.66 and a beta of 2.37. The stock has a 50 day moving average price of $30.49 and a 200 day moving average price of $22.87.
Oscar Health (NYSE:OSCR – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $1.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.40 by $0.70. The firm had revenue of $4.88 billion during the quarter, compared to analysts’ expectations of $4.73 billion. Oscar Health had a net margin of 3.60% and a return on equity of 38.45%. The company’s revenue for the quarter was up 70.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.89) earnings per share. Sell-side analysts forecast that Oscar Health, Inc. will post 1.54 EPS for the current fiscal year.
Institutional Investors Weigh In On Oscar Health
Analyst Ratings Changes
A number of research firms have commented on OSCR. Zacks Research upgraded Oscar Health from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 6th. Robert W. Baird set a $27.00 target price on Oscar Health in a research report on Friday, August 7th. UBS Group lifted their target price on Oscar Health from $20.00 to $26.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Wall Street Zen upgraded Oscar Health from a “buy” rating to a “strong-buy” rating in a research note on Sunday, June 14th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and set a $30.00 price objective on shares of Oscar Health in a report on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $26.22.
Get Our Latest Stock Report on OSCR
Oscar Health Company Profile
Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.
The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.
Further Reading
- Five stocks we like better than Oscar Health
- Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
- Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock
- Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement
- Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
Receive News & Ratings for Oscar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oscar Health and related companies with MarketBeat.com's FREE daily email newsletter.
